AR049186A1 - Derivados de oxazol como moduladores de ppar - Google Patents
Derivados de oxazol como moduladores de pparInfo
- Publication number
- AR049186A1 AR049186A1 ARP050102114A ARP050102114A AR049186A1 AR 049186 A1 AR049186 A1 AR 049186A1 AR P050102114 A ARP050102114 A AR P050102114A AR P050102114 A ARP050102114 A AR P050102114A AR 049186 A1 AR049186 A1 AR 049186A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- halogen
- substituted
- alkoxy
- aryl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/08—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D263/10—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/08—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D263/10—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D263/14—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
Abstract
Composiciones farmacéuticas que comprenden estos compuestos, y métodos para utilizar tales compuestos con el fin de tratar o prevenir enfermedades o desordenes asociados con la actividad de las familias del Receptor Activado por Proliferador de Peroxisoma (PPAR), en particular la actividad de PPARd. Reivindicacion 1: Un compuesto de la formula (1), en donde: p es un entero seleccionado de 0 a 3; L2 se selecciona a partir de -XOX-, -XS(O)0-2X- y -XS(O)0-2XO-; en donde X se selecciona independientemente a partir de un enlace y alquileno C1-4; en donde cualquier alquileno de L2 puede estar opcionalmente sustituido por 1 a 3 radicales seleccionados a partir de halogeno, alquilo C1-6, alcoxilo C1-6, alquilo C1-6 sustituido por halogeno, y alcoxilo C1-6 sustituido por halogeno; R13 se selecciona a partir de halogeno, alquilo C1-6, alcoxilo C1-6, hidroxi-alquilo C1-6, alquilo C1-6 sustituido por halogeno, alcoxilo C1-6 sustituido por halogeno, arilo C6-10, heteroarilo C5- 10, cicloalquilo C3-12, y heterocicloalquilo C3-8; en donde cualquier arilo, heteroarilo, cicloalquilo, y heterocicloalquilo de R13 está opcionalmente sustituido con 1 a 3 radicales independientemente seleccionados a partir de halogeno, nitro, ciano, alquilo C1-6, alcoxilo C1-6, hidroxi-alquilo C1-6, alquilo C1-6 sustituido por halogeno, y alcoxilo C1-6 sustituido por halogeno; R14 se selecciona a partir de -XOXC(O)OR17 y -XC(O)OR17; en donde X es un enlace o alquileno C1-4; y R17 se selecciona a partir de hidrogeno y alquilo C1-6; R15 y R16 se seleccionan independientemente a partir de -R18 y -YR18; en donde Y se selecciona a partir de alquileno C1-6, alquenileno C2-6, alquinileno C2-6, -C(O)NR17- y -OX-; y X es un enlace o alquileno C1-4; R17 se selecciona a partir de hidrogeno y alquilo C1-6; y R18 se selecciona a partir de cicloalquilo C3-12, hetero-ciclo-alquilo C3-, arilo C6-10, y hetero-arilo C5-13; o R15 y R16, junto con los átomos con los que están unidos R15 y R16, forman un heteroarilo C5-14 bicíclico o tricíclico fusionado; en donde cualquier arilo, hetero-arilo, cicloalquilo, y hetero-cicloalquilo de R18, o la combinacion de R15 y R16, está opcionalmente sustituido con 1 a 3 radicales independientemente seleccionados a partir de halogeno, nitro, ciano, alquilo C1-6, alcoxilo C1-6, tioalquilo C1-6, hidroxi-alquilo C1-6, alquilo C1-6 sustituido por halogeno, alcoxilo C1-6 sustituido por halogeno, cicloalquilo C3-12, hetero- cicloalquilo C3-8, arilo C6-10, hetero-arilo C5-13, -XS(O)0-2R17, -XS(O)0-2XR19, XNR17R17, -XNR17S(O)0-2R17, -XNR17C(O)R17, XC(O)NR17R17, -XNR17C(O)R19, -XC(O)NR17R19, -XC(O)R19, -XNR17XR19, y XOXR19; en donde cualquier sustituyente de arilo, heteroarilo, cicloalquilo, o heterocicloalquilo está además sustituido opcionalmente con 1 a 3 radicales independientemente a partir de halogeno, nitro, ciano, alquilo C1-6, alcoxilo C1-6, tioalquilo C1-6, hidroxi-alquilo C1-6, alquilo C1-6 sustituido por halogeno, y alcoxilo C1-6, sustituido por halogeno; en donde X es un enlace o alquileno C1-4; R17 se selecciona a partir de hidrogeno y alquilo C1-4, y R19 se selecciona a partir de cicloalquilo C3-12, heterocicloalquilo C3-8, arilo C6-10, y heteroarilo C5-10; en donde cualquier arilo, heteroarilo, cicloalquilo, o heterocicloalquilo de R19 está opcionalmente sustituido con 1 a 3 radicales independientemente seleccionados a partir de halogeno, nitro, ciano, alquilo C1-6, alcoxilo C1-6, alquilo C1-6 sustituido por halogeno, y alcoxilo C1-6 sustituido por halogeno; y las sales farmacéuticamente aceptables, hidratos, solvatos, isomeros, y profármacos del mismo.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US57413704P | 2004-05-24 | 2004-05-24 | |
US64967105P | 2005-02-02 | 2005-02-02 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR049186A1 true AR049186A1 (es) | 2006-07-05 |
Family
ID=35450825
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP050102114A AR049186A1 (es) | 2004-05-24 | 2005-05-23 | Derivados de oxazol como moduladores de ppar |
Country Status (17)
Country | Link |
---|---|
US (1) | US20070244130A1 (es) |
EP (1) | EP1749003A4 (es) |
JP (1) | JP2008500354A (es) |
KR (1) | KR20070043705A (es) |
AR (1) | AR049186A1 (es) |
AU (2) | AU2005247930B2 (es) |
BR (1) | BRPI0511527A (es) |
CA (1) | CA2563819A1 (es) |
EC (1) | ECSP067019A (es) |
IL (1) | IL179375A0 (es) |
MA (1) | MA28900B1 (es) |
MX (1) | MXPA06013589A (es) |
NO (1) | NO20065983L (es) |
PE (1) | PE20060362A1 (es) |
RU (1) | RU2412175C2 (es) |
TW (1) | TW200600505A (es) |
WO (1) | WO2005116016A1 (es) |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2006306420A1 (en) * | 2005-10-25 | 2007-05-03 | Merck Sharp & Dohme Corp. | Combination of a dipeptidyl peptidase-4 inhibitor and an anti-hypertensive agent for the treatment of diabetes and hypertension |
EP1945633A1 (en) * | 2005-11-07 | 2008-07-23 | Irm Llc | Compounds and compositions as ppar modulators |
EA200901099A1 (ru) | 2007-02-22 | 2010-04-30 | Айрм Ллк | Соединения и способы модулирования сопряженных с g-белком рецепторов |
EP1972335A1 (en) * | 2007-03-23 | 2008-09-24 | Krka | Solid dosage forms comprising aliskiren and pharmaceutically acceptable salts thereof |
KR100860561B1 (ko) * | 2007-05-02 | 2008-09-26 | 경희대학교 산학협력단 | 컴파운드 k 및 메트포민을 유효성분으로 포함하는당뇨병의 예방 및 치료용 약학적 조성물 |
WO2010045563A2 (en) * | 2008-10-16 | 2010-04-22 | Metabolous Pharmaceuticals, Inc. | Combination therapies for the treatment of obesity |
US20100113603A1 (en) * | 2008-10-16 | 2010-05-06 | Aronne Louis J | Combination therapies for the treatment of obesity |
US20100113581A1 (en) * | 2008-10-16 | 2010-05-06 | Aronne Louis J | Combination therapies for the treatment of obesity |
US20100113583A1 (en) * | 2008-10-16 | 2010-05-06 | Aronne Louis J | Combination therapies for the treatment of obesity |
US20100331419A1 (en) * | 2009-06-25 | 2010-12-30 | Aronne Louis J | Combination Therapies for the Treatment of Obesity |
WO2010151565A2 (en) * | 2009-06-26 | 2010-12-29 | Metabolous Pharmaceuticals, Inc. | Combination therapies for the treatment of obesity |
WO2011008490A2 (en) * | 2009-06-29 | 2011-01-20 | Metabolous Pharmaceuticals, Inc. | Combination therapies for the treatment of obesity |
WO2011009115A2 (en) * | 2009-07-17 | 2011-01-20 | Metabolous Pharmaceuticals, Inc. | Combination therapies for the treatment of obesity |
NZ597895A (en) * | 2009-08-05 | 2012-11-30 | Daiichi Sankyo Co Ltd | Amide derivative |
WO2011016470A1 (ja) * | 2009-08-05 | 2011-02-10 | 第一三共株式会社 | スルホン誘導体 |
US20110082407A1 (en) * | 2009-10-01 | 2011-04-07 | Aronne Louis J | Combination Therapies for the Treatment of Obesity |
US8652527B1 (en) | 2013-03-13 | 2014-02-18 | Upsher-Smith Laboratories, Inc | Extended-release topiramate capsules |
US9101545B2 (en) | 2013-03-15 | 2015-08-11 | Upsher-Smith Laboratories, Inc. | Extended-release topiramate capsules |
CN103724289B (zh) * | 2013-12-23 | 2015-08-19 | 同济大学 | (e)-2,4,5-三取代-(1-丙烯基)噁唑环类化合物及合成方法和应用 |
CN104402839B (zh) * | 2014-10-20 | 2016-11-02 | 同济大学 | 一种(e)-2,4,5-三取代-(1-丙烯基)噁唑环类化合物及其制备方法 |
CN108760940A (zh) * | 2018-08-03 | 2018-11-06 | 安徽省金楠医疗科技有限公司 | 一种硫酸氢氯吡格雷检测方法 |
CN112521384B (zh) * | 2021-01-13 | 2021-11-02 | 湖北大学 | 溶剂热一锅法合成苯并噻嗪并环戊二烯衍生物 |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4325959A (en) * | 1979-08-09 | 1982-04-20 | The Dow Chemical Company | Hypoglycemic 4-(((1,3,4, thiadiazolyl)thio)methyl)benzoic acids, ester and amides |
JPH0662590B2 (ja) * | 1986-09-19 | 1994-08-17 | 久光製薬株式会社 | 新規なベンズオキサゾ−ル誘導体 |
IT1229491B (it) * | 1988-12-28 | 1991-09-03 | Roussel Maestretti S P A Ora R | Derivati della 1,2,5,6-tetraidropiridina, loro procedimento di preparazione e loro impiego come sostanze medicinali |
NZ236474A (en) * | 1989-12-20 | 1993-07-27 | Bristol Myers Squibb Co | 4,5-diphenyl-2-oxazole octanoic, nonanoic and decanoic acid and ester derivatives, preparation and pharmaceutical compositions thereof |
US5262540A (en) * | 1989-12-20 | 1993-11-16 | Bristol-Myers Squibb Company | [2(4,5-diaryl-2 oxazoyl substituted phenoxy alkanoic acid and esters |
IT1248528B (it) * | 1991-06-21 | 1995-01-19 | Pierrel Spa | Derivati di eteri e tioeteri (etero) aromatici aventi attivita` antiiperlipidemica, procedimento per la loro preparazione e composizioni farmaceutiche che li contengono. |
JPH06206805A (ja) * | 1992-02-17 | 1994-07-26 | Hisamitsu Pharmaceut Co Inc | チロシナーゼ阻害剤及びそれを用いた皮膚外用剤 |
US5380738A (en) * | 1993-05-21 | 1995-01-10 | Monsanto Company | 2-substituted oxazoles further substituted by 4-fluorophenyl and 4-methylsulfonylphenyl as antiinflammatory agents |
JPH11147881A (ja) * | 1997-08-21 | 1999-06-02 | Sankyo Co Ltd | ジヒドロベンゾキノン骨格を有する除草性アゾール誘導体 |
JP2002348281A (ja) * | 2001-03-23 | 2002-12-04 | Takeda Chem Ind Ltd | 5員複素環アルカン酸誘導体 |
-
2005
- 2005-05-20 PE PE2005000563A patent/PE20060362A1/es not_active Application Discontinuation
- 2005-05-23 TW TW094116634A patent/TW200600505A/zh unknown
- 2005-05-23 AR ARP050102114A patent/AR049186A1/es unknown
- 2005-05-24 BR BRPI0511527-2A patent/BRPI0511527A/pt not_active IP Right Cessation
- 2005-05-24 WO PCT/US2005/018166 patent/WO2005116016A1/en active Application Filing
- 2005-05-24 EP EP05775612A patent/EP1749003A4/en not_active Withdrawn
- 2005-05-24 US US11/597,260 patent/US20070244130A1/en not_active Abandoned
- 2005-05-24 JP JP2007515254A patent/JP2008500354A/ja active Pending
- 2005-05-24 CA CA002563819A patent/CA2563819A1/en not_active Abandoned
- 2005-05-24 MX MXPA06013589A patent/MXPA06013589A/es not_active Application Discontinuation
- 2005-05-24 AU AU2005247930A patent/AU2005247930B2/en not_active Ceased
- 2005-05-24 KR KR1020067024605A patent/KR20070043705A/ko not_active Application Discontinuation
- 2005-05-24 RU RU2006145893/04A patent/RU2412175C2/ru not_active IP Right Cessation
-
2006
- 2006-11-16 IL IL179375A patent/IL179375A0/en unknown
- 2006-11-21 EC EC2006007019A patent/ECSP067019A/es unknown
- 2006-12-12 MA MA29525A patent/MA28900B1/fr unknown
- 2006-12-22 NO NO20065983A patent/NO20065983L/no not_active Application Discontinuation
-
2009
- 2009-07-01 AU AU2009202673A patent/AU2009202673A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
ECSP067019A (es) | 2006-12-29 |
US20070244130A1 (en) | 2007-10-18 |
EP1749003A1 (en) | 2007-02-07 |
PE20060362A1 (es) | 2006-05-15 |
WO2005116016A1 (en) | 2005-12-08 |
AU2005247930A1 (en) | 2005-12-08 |
TW200600505A (en) | 2006-01-01 |
EP1749003A4 (en) | 2010-05-05 |
BRPI0511527A (pt) | 2008-01-02 |
RU2006145893A (ru) | 2008-06-27 |
CA2563819A1 (en) | 2005-12-08 |
NO20065983L (no) | 2007-02-05 |
AU2009202673A1 (en) | 2009-07-23 |
KR20070043705A (ko) | 2007-04-25 |
RU2412175C2 (ru) | 2011-02-20 |
AU2005247930B2 (en) | 2009-04-02 |
IL179375A0 (en) | 2007-03-08 |
MA28900B1 (fr) | 2007-10-01 |
JP2008500354A (ja) | 2008-01-10 |
MXPA06013589A (es) | 2007-03-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR049186A1 (es) | Derivados de oxazol como moduladores de ppar | |
AR049284A1 (es) | Compuestos derivados de 1,3-tiazol; composiciones farmaceuticas que los contienen y su uso en la preparacion de medicamentos para el tratamiento de enfermedades asociadas a la actividad de los ppard | |
AR048789A1 (es) | Derivados de oxazol y sus composiciones como moduladores de receptor activado de proliferador de peroxisoma (ppar) | |
AR064561A1 (es) | Derivados de 2-aza-biciclo[3.1.0]hexano y su uso en la preparacion de un medicamento para el tratamiento de enfermedades relacionadas con disfunciones generales del sistema de la orexina. | |
AR078756A1 (es) | Moduladores alostericos positivos (map) | |
AR052887A1 (es) | Derivados de tiazol, composiciones farmaceuticas que los contienen y su uso en la fabricacion de un medicamento para tratar enfermedades mediadas por la inhibicion de la protein quinasa | |
AR060633A1 (es) | Derivados de furo[3, 2-d]pirimidina, furo[2, 3-d]pirimidina, tieno[3, 2-d]pirimidina y tieno[2, 3-d]pirimidina, metodos para su preparacion, composiciones farmaceuticas y obtencion de las mismas, el uso de estos derivados en la fabricacion de medicamentos, kits y productos para el tratamiento de enf | |
WO2009082268A3 (ru) | ЛИГАНДЫ α-АДРЕНОЦЕПТОРОВ, ДОПАМИНОВЫХ, ГИСТАМИНОВЫХ, ИМИДАЗОЛИНОВЫХ И СЕРОТОНИНОВЫХ РЕЦЕПТОРОВ И ИХ ПРИМЕНЕНИЕ | |
AR051596A1 (es) | Compuestos heterociclicos condensados nitrogenados como inhibidores de la actividad del receptor canabinoide 1; composiciones farmaceuticas que los contienen y su empleo en la preparacion de medicamentos para el tratamiento de trastornos alimentarios | |
PE20081454A1 (es) | Derivados de pirazol como moduladores del receptor 5-ht2a de serotonina utiles para el tratamiento de los transtornos relacionados con dicho receptor | |
AR036044A1 (es) | Compuestos piranoindazoles, composiciones farmaceuticas y su uso para la manufactura de un medicamento para el tratamiento del glaucoma | |
AR059428A1 (es) | Pirazoles para el tratamiento de enfermedades mediadas por la modulacion de los receptores de histamina h3 y una composicion farmaceutica que los comprende. | |
AR035892A1 (es) | Derivados de oxazol, proceso para su preparacion, composiciones farmaceuticas que los comprenden, y el uso de dichos compuestos en la preparacion de medicamentos | |
AR043111A1 (es) | Derivados monoacilados de o-fenilendiaminas | |
AR067662A1 (es) | Derivados de benzo[d]isoxazol-3-il-piperidina, medicamentos que los contienen y usos terapeuticos para enfermedades asociadas al sistema nervioso. | |
AR085471A1 (es) | Compuestos de bis(fluoroalquil)-1,4-benzodiazepinona | |
AR052902A1 (es) | Derivados de piridazina, composicion farmaceutica que los contiene y su uso como agentes terapeuticos para enfermedades mediadas por la estearoil-coa desaturasa | |
AR043998A1 (es) | Acidos fenoxiaceticos | |
AR099640A1 (es) | Derivados de pirrolopiridina o pirazolopiridina | |
AR056204A1 (es) | Derivados de indano como antagonistas de receptores de mch, metodos para su preparacion, intermediarios de sintesis de los mismos, composiciones farmaceuticas que los comprenden y su uso en la fabricacion de medicamentos para el tratamiento de enfermedades relacionadas | |
AR051997A1 (es) | Heterociclos triciclicos, su obtencion y uso delos mismos c omo agentes farmaceuticos | |
UY27336A1 (es) | Derivados de 4-piperacinilindol con afinidad receptora de 5-ht6 | |
AR078550A1 (es) | DERIVADOS DE AZETIDINA Y PIPERIDINA, COMPOSICIONES FARMACEUTICAS QUE LOS COMPRENDEN Y SU USO PARA EL TRATAMIENTO DE AFECCIONES MEDIADAS POR LA MODULACIoN DE GPR119 | |
AR050274A1 (es) | Derivados triciclicos del indeno-pirrol como moduladores de la serotonina | |
AR037907A1 (es) | Derivados de azaindolilalquilamina como ligandos de 5-hidroxitriptamina-6 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |